The Relative Strength (RS) Rating for BioCryst Pharmaceuticals stock climbed into a new percentile Friday, with a rise from 64 to 84.
When looking for the best stocks to buy and watch, one factor to watch closely is relative price strength.
IBD's unique RS Rating identifies technical performance by using a 1 (worst) to 99 (best) score that indicates how a stock's price performance over the last 52 weeks matches up against the rest of the market.
History shows that the top-performing stocks often have an RS Rating of at least 80 as they launch their biggest climbs.
See How IBD Helps You Make More Money In Stocks
Is BioCryst Pharmaceuticals Stock A Buy?
BioCryst Pharm stock is trying to complete a consolidation with a 15.53 buy point. The biotech stock recently retook its 200-day moving line. See if the stock can clear the breakout price in heavy volume. Read "Looking For The Next Big Stock Market Winners? Start With These 3 Steps" for more tips.
The biotech firm posted 0% earnings growth last quarter. Revenue gains came in at 85%.
BioCryst Pharmaceuticals earns the No. 122 rank among its peers in the Medical-Biomed/Biotech industry group. Genmab ADR and Harmony Biosciences are also among the group's highest-rated stocks. For more industry news, check out "Biotech And Pharmaceutical Industry And Stock News."
